Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02925793 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)
A Phase 2 study, sponsored by DS Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 327
- Enrollment target
NCT02925793: Completed Phase 2 study, sponsored by DS Biopharma.
NCT02925793 is a Phase 2 study that has completed, run by DS Biopharma. The registered enrollment target is 327 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (146% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02925793, a Phase 2 study, has completed, sponsored by DS Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 327 participants
- Enrollment target
Study Summary
The purpose of this randomized, double blind, placebo controlled, parallel group study is to compare the safety and efficacy of topically applied DS107 cream (1% and 5%) versus vehicle cream, in the treatment of adult patients with mild to moderate Atopic Dermatitis (AD).
Primary Outcome
Change from baseline in Numeric Rating Scale (NRS) for Pruritus in treated population compared to vehicle population at Week 8. Severity of pruritus related to atopic dermatitis (AD) was self-assessed by patients daily using the NRS. Patients were asked to estimate the intensity of pruritus at its worst over the previous 24 hours. The Pruritus NRS is a single-question assessment tool that was used to assess the patient's worst itch as a result of AD in the previous 24 hours. Patients scored thei
Interventions
- DRUG DS107
- OTHER Vehicle cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-07 |
| Phase | Phase 2 |
What the finished NCT02925793 record still lists
NCT02925793 is an interventional study that assigns participants to a tested intervention. The registered 327 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (146% higher).
The record links to 0 conditions, and to 2 interventions - of which DS107 is the first listed.
NCT02925793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02925793 about?
NCT02925793 is a clinical study titled "Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)". The purpose of this randomized, double blind, placebo controlled, parallel group study is to compare the safety and efficacy of topically applied DS107 cream (1% and 5%) versus vehicle cream, in the treatment of adult patients with mild to moderate Atopic Dermatitis (AD).
What is the current status of trial NCT02925793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 327 participants. The study started on 2016-12. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02925793?
The interventions under investigation include: DS107 (DRUG), Vehicle cream (OTHER).
Who is sponsoring clinical trial NCT02925793?
This trial is sponsored by DS Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02925793's enrollment target sits among peer trials
327 146th of 2000 higher than 1,854 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486378 · 327 participants · Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- NCT06370182 · 327 participants · NA
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia